Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Amlenetug Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Amlenetug: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pizuglanstat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Pizuglanstat: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sacibertinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Sacibertinib: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Rifaquizinone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Rifaquizinone: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Futuximab/Modotuximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Futuximab/Modotuximab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Favezelimab/Pembrolizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Favezelimab/Pembrolizumab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Eicosapentaenoic acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Eicosapentaenoic acid: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Valproic Acid/Prednisone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Valproic Acid/Prednisone: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pegcrisantaspase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Pegcrisantaspase: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Raxatrigine hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Raxatrigine hydrochloride: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Patidegib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Patidegib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Epaminurad Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Epaminurad: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.